Table 1.
Patient/tumour characteristics and treatment summary
| Total | 72 | |
|---|---|---|
| Follow-up | Median | 25 months |
| Range | 6–70 months | |
| Age | Median | 60 |
| Range | (39–75) | |
| Sex | Male | 61 (84.7 %) |
| Female | 11 (15.3 %) | |
| Smoking history | > 10 pack/year | 41 (56.9 %) |
| ≤ 10 pack/year | 7 (9.7 %) | |
| Pack/year not known | 11 (15.3 %) | |
| Non-smoker | 13 (18.1 %) | |
| Alcohol History | Heavy (> 3 standard drinks) | 22 (30.6 %) |
| Non-heavy (≤ 3 standard drinks) | 34 (47.2 %) | |
| Non drinker | 11 (15.3 %) | |
| No record | 5 (6.9 %) | |
| Primary tumour site | Oropharynx | 47 (65.3 %) |
| Larynx | 16 (22.2 %) | |
| Hypopharynx | 6 (8.3 %) | |
| Oral cavity | 3 (4.2 %) | |
| T stage | 1 | 6 (8.3 %) |
| 2 | 25 (34.7 %) | |
| 3 | 31 (43.1 %) | |
| 4 | 10 (13.9 %) | |
| N stage | 0 | 9 (12.5 %) |
| 1 | 11 (15.3 %) | |
| 2 | 47 (65.3 %) | |
| 3 | 5 (6.9 %) | |
| Staging (Overall) | III | 18 (25.0 %) |
| IV | 54 (75.0 %) | |
| Treatment | Radiotherapy + chemotherapy | 57 (79.2 %) |
| Chemoradiotherapy (Weekly Cisplatin) | 42 (58.3 %) | |
| Chemoradiotherapy (Weekly Carboplatin) | 12 (16.7 %) | |
| Chemoradiotherapy (3 weekly Cisplatin; Carboplatin + 5-Fluorouracil or Carboplatin + Vinorelbine | 3 (4.2 %) | |
| Induction chemotherapy | 17 (23.6 %) | |
| Radiotherapy + Cetuximab | 15 (20.8 %) |